Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma
← catalyst calendarSponsored by Iovance Biotherapeutics, Inc. (industry) · IOVA — their whole pipeline →.
Phase
Phase 2
Status
Terminated
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
210actual
Sites
43
Countries
France, Germany, Italy +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
After reviewing available safety and efficacy data to date, Iovance concluded the study reached the required number of events for evaluation of study endpoints.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2017-06-22 | actual | When the study began enrolling |
| Primary completion | 2025-08-22 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-08-22 | actual | The whole study's end, after follow-up |
| First posted | 2017-04-11 | actual | When this record first appeared on the registry |
| Results posted | 2026-07-31 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-07-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Cervical Carcinoma
Interventions
- Biological: LN-145 — also filed as TIL, autologous tumor infiltrating lymphocytes
- Biological: LN-145 + pembrolizumab — also filed as TIL, autologous tumor infiltrating lymphocytes; pembrolizumab (anti-PD-1 immunotherapy)
Primary outcomes
what the primary-completion date above is the date OFCohort 1 and 2: Objective Response Rate
measured Up to 60 months
Cohort 3: Adverse Events
measured Up to 60 months
Cohort 4: Adverse Events
measured Up to 60 months
Cohort 4: Efficacy/Objective Response Rate
measured Up to 60 months
Cohort 5: Adverse Events
measured Up to 60 months
Cohort 5: Efficacy/Objective Response Rate
measured Up to 60 months
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2025-08-14 · 5.6 MB · Prot_000.pdf
Statistical Analysis Planposted 2025-12-10 · 668 KB · SAP_001.pdf
Permalink · IOVA's whole pipeline · Catalyst calendar · Every registered study · What changed